Inhibitors of KRAS G12C and methods of using the same

US10640504B2 · kind B2 · utility

Assignee

• AMGEN INC. · US

Inventors

• Brian Alan LANMAN · Calabasas, US
• Shon Booker · Thousand Oaks, US
• Clifford GOODMAN · Thousand Oaks, US
• Anthony B. Reed · Newbury Park, US
• Jonathan D. Low · Thousand Oaks, US
• Hui-Ling Wang · Thousand Oaks, US
• Ning Chen · Thousand Oaks, US
• Ana Elena Minatti · Santa Monica, US
• Ryan Wurz · Newbury Park, US
• Victor J. Cee · Thousand Oaks, US

Key dates

• Filing date: Sep 7, 2018
• Grant date: May 5, 2020
• Expiry date: Sep 7, 2038

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K2300/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.